Literature DB >> 2243341

A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice.

H E Shannon1, S C Peters.   

Abstract

The effects of cholinesterase inhibitors, cholinergic agonists, dopaminergic agonists and dopaminergic antagonists on the hyperactivity produced by the muscarinic cholinergic antagonist scopolamine were evaluated in mice. Scopolamine (0.3-10 mg/kg) produced a dose-related increase in locomotor activity, with a peak effect at 3.0 mg/kg. The cholinesterase inhibitor physostigmine (0.03-0.175 mg/kg) was without effect on locomotor activity when administered alone, whereas the cholinesterase inhibitor tetrahydroaminoacridine hydrate (0.3-10 mg/kg) decreased locomotor activity. Both physostigmine and tetrahydroaminoacridine hydrate attenuated the effects of scopolamine. Administered alone, the cholinergic agonists oxotremorine (0.01-0.3 mg/kg) and RS86 (0.1-3.0 mg/kg) produced dose-related decreases in locomotor activity, whereas pilocarpine (0.3-10 mg/kg) had no effect on locomotor activity. None of these three muscarinic agonists significantly attenuated the hyperactivity produced by scopolamine. Administered alone, the dopaminergic agonists quinpirole (0.003-0.1 mg/kg), S-(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (0.3-10 mg/kg) and SKF 38393 (8-64 mg/kg) had no significant effect on activity, whereas apomorphine (0.3-10 mg/kg) and d-amphetamine (0.1-3.0 mg/kg) increased activity. Quinpirole, apomorphine and S-(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine produced dose-related reversals of the increases in locomotor activity produced by scopolamine. The hyperactivity effects of d-amphetamine were approximately additive with scopolamine, whereas SKF 38393 did not significantly affect scopolamine. The mixed D1/D2 dopaminergic antagonist haloperidol (0.003-3.0 mg/kg) and the selective D1 antagonist SCH 23390 (0.01-0.3 mg/kg) produced dose-related decreases in locomotor activity when administered alone, and also produced dose-related reversals of the hyperactivity produced by scopolamine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243341

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Authors:  Segev Barak; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

2.  Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor.

Authors:  T Miyakawa; M Yamada; A Duttaroy; J Wess
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

3.  Cocaine reduces cytochrome oxidase activity in the prefrontal cortex and modifies its functional connectivity with brainstem nuclei.

Authors:  M E Vélez-Hernández; E Padilla; F Gonzalez-Lima; C A Jiménez-Rivera
Journal:  Brain Res       Date:  2014-01-13       Impact factor: 3.252

4.  The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.

Authors:  Yotam Sagi; Noam Driguès; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

5.  The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys.

Authors:  Scott J Webster; Christina A Wilson; Chih-Hung Lee; Eric G Mohler; Alvin V Terry; Jerry J Buccafusco
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice.

Authors:  Philipp Singer; Benjamin K Yee
Journal:  Pharmacol Biochem Behav       Date:  2011-12-21       Impact factor: 3.533

7.  Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in rats.

Authors:  Gregory P Mark; Anthony E Kinney; Michele C Grubb; Xiaoman Zhu; Deborah A Finn; Sarah L Mader; S Paul Berger; Anita J Bechtholt
Journal:  Brain Res       Date:  2006-10-13       Impact factor: 3.252

8.  Intra-accumbens infusion of a muscarinic antagonist reduces food intake without altering the incentive properties of food-associated cues.

Authors:  Michelle L Perry; Matthew E Andrzejewski; Susan M Bushek; Brian A Baldo
Journal:  Behav Neurosci       Date:  2010-02       Impact factor: 1.912

9.  Biphasic locomotor effects of the dopamine D1 agonist SKF 38393 and their attenuation in non-habituated mice.

Authors:  E Tirelli; P Terry
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Mecamylamine reverses physostigmine-induced attenuation of scopolamine-induced hyperactivity.

Authors:  M F O'Neill; A G Fernández; R W Gristwood; J M Palacios
Journal:  J Neural Transm Gen Sect       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.